Advances on the role of interleukin-6 in the pathogenesis of psoriasis

doi:10.3969/j.issn.1674-490X.2016.05.010

Abstract

Abstract: Psoriasis is a chronic inflammatory skin disease characterized by increased epidermal thickness.The causes of the disease are complex,many people believe it is an autoimmune-related skin disease.The course of the disease is long,and the recurrent attacks of the disease are easy.Interleukin 6(IL-6)can induct differentiation and proliferation of keratinocytes and induce the activation of T cells,stimulate keratinocytes to produce cytokines including vascular endothelial growth factor(VEGF),IL-8,these cytokines may play important roles in the development or aggravation of psoriasis,IL-6 is also related to psoriasis-caused osteoporosis,hyperlipidemia,and cardiovascular diseases.

Key words: psoriasis, interleukin-6, T cell, keratinocyte

CLC Number:

SUN Haiyan,DING Qiuyun,SHI Yijun,CHU Ruiqi. Advances on the role of interleukin-6 in the pathogenesis of psoriasis[J]. Medical Reserch and Education, 2016, 33(5): 44-48.

References

[1] LEE S Y,BUHIMSCHI I A,DULAY A T,et al.IL-6 trans-signaling system in intra-amniotic inflammation,preterm birth,and preterm birth and preterm premature rupture of the membranes[J].J Immunol,2011,186(5):3226-3236.DOI:10.4049/jimmunol.1003587.
[2] ANDREA S,SERGIO C,ANDREA C.IL-6 as a druggable target in psoriasis:focus on pustular variants[J].Journal of Immunology Research,2014,964069:1-10.DOI:10.1155/2014/964069.
[3] SCHELLER J,CHALARIS A,SCHMIDT-ARRAS D,et al.The pro- and anti-inflammatory properties of the cytokine interleukin-6[J].Biochim Biophys Acta,2011,1813(5):878-888.DOI:10.1016/j.bbamcr.2011.01.034.
[4] DAYER J M,CHOY E.Therapeutic targets in rheumatoid arthritis:the interleukin-6 receptor[J].Rheumatology(oxford),2010,49(1):15-24.DOI:10.1093/rheumatology/kep329.
[5] LOWES M A,SUAREZ-FARINAS M,KRUEGER J G.Immunology of psoriasis[J].Annu Rev Immunol,2014,32:227-255.DOI:10.1146/annurev-immunol-032713-120225.
[6] TAKAHASHI H,TSUJI H,HASHIMOTO Y.Serum cytokines and growth factor levels in Japanese patients with psoriasis[J].Clinical and Experimental Dermatology,2010,35(6):645-649.DOI:10.1111/j.1365-2230.2009.03704.
[7] FUJISHIMA S,WATANABE H,KAWAGUCHI M,et al.Involvement of IL-17F via the induction of IL-6 in psoriasis[J].Arch Dermatol Res,2010,302(7):499-505.DOI:10.1007/s00403-010-1033-8.
[8] CROXFORD A L,KARBACH S,KURSCHUS F C.IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions[J].J Invest Dermatol,2014,134(3):728-735.DOI:10.1038/jid.2013.404.
[9] NIEDBALA W,ALVES-FILHO J C,FUKADA S Y,et al.Regulation of type 17 helper T-cell function by nitric oxide during inflammation[J].Proc Natl Acad Sci USA,2011,108(22):9220-9225.DOI:10.1073/pnas.1100667108.
[10] ATAIE-KACHOIE P,POURGHOLAMI M H,MORRIS D L.Inhibition of the IL-6 signaling pathway:a strategy to combat chronic inflammatory diseases and cancer[J].Cytokine and Growth Factor,2013,24(2):163-173.DOI:10.1016/j.cytogfr.2012.09.001.
[11] LUTING Y,BING L,DANG E,et al.Impaired function of regulatory T cells in patients with is mediated by phosphorylation of STAT3[J].J Dermatol Sci,2016,81(2):85-92.DOI:10.1016/j.jdermsci.2015.11.007.
[12] MABUCHI T,CHANG T W,QUINTER S,et al.Chemokine receptors in the pathogenesis and therapy of psoriasis[J].J Dermatol Sci,2012,65(1):4-11.DOI:10.1016/j.jdermsci.2011.11.007.
[13] SCHON M P,RUZICKA T.Psoriasis:the plot thickens[J].Nat Immunol,2001,2(2):91.
[14] VERKHRATSKY A,BURNSTOCK G.Biology of purinergic signalling:its ancient evolutionary roots,its omnipresence and its multiple functional significance[J].Bioessays,2014,36(7):697-705.DOI:10.1002/bies.201400024.
[15] ISHIMARU M,TSUKIMOTO M,HARADA H,et al.Involvement of P2Y11 receptor in IFN-γ-induced IL-6 production in human keratinocytes[J].Eur J Pharmacol,2013,703(1-3):67-73.DOI:10.1016/j.ejphar.2013.02.020.
[16] FLISIAK I,ZANIEWSKI P,ROGALSKA M,et al.Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales[J].Cytokine,2013,61(2):690.DOI:10.1016/j.cyto.2012.11.012.
[17] CANAVESE M,ALTRUDA F,RUZICKA T,et al.Vascular endothelial growth factor(VEGF)in the pathogenesis of psoriasis-A possible target for novel therapier?[J].J Dermatol Sci,2010,58(3):171-176.DOI:10.1016/j.jdermsci.2010.03.023.
[18] ELIAS P M,ARBISER J,BROWN B E,et al.Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis,dermal angiogenesis and the development of epidermal hyperplasis: implications for the pathogenesis of psoriasis[J].Am J Pathol,2008,173(3):689-699.DOI:10.2353/ajpath.2008.080088.
[19] BALTA I,BALTA S,DEMIRKOL S,et al.Aortic arterial stiffness is a moderate predictor of cardiovascular disease in patients with psoriasis vulgaris[J].Angiology,2014,65(1):74-78.DOI:10.1177/0003319713485805.
[20] TORRES T,SELORES M.Does treatment of metabolic syndrome components improve psoriasis?Report of three cases[J].Eur J Dermatol,2012,22(2):270-272.DOI:10.1684/ejd.2011.1614.
[21] QADIM H H,GOFOROUSHAN F,NEJAD S B,et al.Study the calcium serum level in patients suffering from psoriasis[J].Pak J Biol Sci,2013,16(6):291-294.
[22] SCHAFER J A,KJESBO N K,GLEASON P P.Formulary review of 2 new biologic agents:tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis[J].J Manag Care Pharm,2010,16(6):402-416.
[23] TOSHIO T,TADAMITSU K.Targeting interleukin-6:all the way to treat autoimmune and inflammatory diseases[J].Inter J Biological Sci,2012,8(9):1227-1236.DOI:10.7150/ijbs.4666.